Kenneth J. Dow

Compliance Officer at CENTURY THERAPEUTICS, INC.

Health Technology

Consumer Services

Commercial Services

Profile

Kenneth J.
Dow is currently the Head-Legal & Compliance at Century Therapeutics, Inc. He previously worked as Vice President-Patent Law at Janssen Biotech, Inc., Vice President-Pharmaceutical Patent Strategy at Johnson & Johnson Law Department Europe, and Vice President-Law at Century Therapeutics, Inc. He has a graduate degree from St. John's University and an undergraduate degree from State University of New York at Buffalo.

Kenneth J. Dow active positions

Companies	Position	Start
CENTURY THERAPEUTICS, INC.	Compliance Officer	-

All active positions of Kenneth J. Dow

Former positions of Kenneth J. Dow

Companies	Position	End
Janssen Biotech, Inc. Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA.	Corporate Officer/Principal	-
Johnson & Johnson Law Department Europe Johnson & Johnson Law Department Europe Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Johnson & Johnson Law Department Europe provides legal services. The private company is based in Buckinghamshire, UK.	Corporate Officer/Principal	-
Century Therapeutics, Inc. /Old/ Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.	General Counsel	-

See the detail of Kenneth J. Dow's experience

Training of Kenneth J. Dow

St. John's University	Graduate Degree
State University of New York at Buffalo	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kenneth J. Dow's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
CENTURY THERAPEUTICS, INC.	Health Technology

Private companies	3
Janssen Biotech, Inc. Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA.	Health Technology
Johnson & Johnson Law Department Europe Johnson & Johnson Law Department Europe Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Johnson & Johnson Law Department Europe provides legal services. The private company is based in Buckinghamshire, UK.	Commercial Services
Century Therapeutics, Inc. /Old/ Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.	Health Technology

See company connections

Stock Market
Insiders
Kenneth J. Dow